Lexicon (LXRX) Top-line Results In Type 1 Diabetes Clinical Trial, Crown Equity Holdings Adds Medica



http://pennyomega.com/img/lxrx.jpg Lexicon Pharmaceuticals, Inc. (LXRX)

Diabetes is a disorder of metabolism—the way the body uses digested food for growth and energy. Most of the food people eat is broken down into glucose, the form of sugar in the blood.

Glucose is vital to your health because it's an important source of energy for the cells that make up your muscles and tissues. It's also your brain's main source of fuel.

The three main types of diabetes are: type 1 diabetes, type 2 diabetes and gestational diabetes.

Type 1 diabetes is a serious condition affecting more than one million people in the United States, both children and adults. Type 1 diabetes is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas. A person who has type 1 diabetes must take insulin daily to live.

Symptoms of type 1 diabetes usually develop over a short period, although beta cell destruction can begin years earlier, and may include increased thirst and urination, constant hunger, weight loss, blurred vision, and extreme fatigue. If not diagnosed and treated with insulin, a person with type 1 diabetes can lapse into a life-threatening diabetic coma, also known as diabetic ketoacidosis.

LXRX reported positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control.

According to LXRX, the results from this study provide a clear demonstration of proof-of-concept of LX4211 as an oral, investigational new drug for type 1 diabetes complementing insulin therapy, and the magnitude of improved glycemic control by several measures, including HbA1c in only four weeks, and lower insulin requirements are highly encouraging and support the progression of LX4211 into late-stage development for type 1 diabetes

LXRX's LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action.


LXRX is focused on developing breakthrough treatments for human disease. LXRX has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by its research team.

More about Lexicon Pharmaceuticals, Inc. (LXRX) at www.lexpharma.com.


http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 420th community website in the U.S., associated with 1870 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.


CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com


http://pennyomega.com/img/bebe.jpg Bebe Stores, Inc. (BEBE)

BEBE was upgraded from Neutral to Buy with a price target of $7.50 by brokerage firm Janney Montgomery Scott


BEBE is a global specialty retailer, which designs, develops and produces a distinctive line of contemporary women’s apparel and accessories under the bebe, BEBE SPORT, bbsp and 2b bebe brand names.

More about Bebe Stores, Inc. (BEBE) at www.bebe.com


http://pennyomega.com/img/adxs.jpg Advaxis, Inc. (ADXS)

ADXS said that the Japan Patent Office issued to the company two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to ADXS' proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

One of the patent applications allowed by the Japan Patent Office covers ADXS' immunotherapy treatments targeting factors that are essential for tumors or metastases to form new blood vessels (angiogenesis) or that are expressed by tumor blood vessels. The second patent applicationcovers the form of a recombinant attenuated auxotrophic Listeria having specific mutations conferring attenuation along with plasmid that complements the genomic mutation and also expresses a protein antigen fused to highly immunogenic Listeria peptides or other strongly immunogenic pathogen-associated peptide sequences.

It has already been established that attacking a tumor's blood supply is an important strategy in preventing the tumor from growing and spreading and the addition of these two patents in Japan further allows ADXS to protect key elements of its proprietary cancer immunotherapies


ADXS' immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.

More about Advaxis, Inc. (ADXS) at www.advaxis.com


Read Full Disclaimer at www.pennyomega.com/disclaimer

14.4.14 16:18


bisher 0 Kommentar(e)     TrackBack-URL

E-Mail bei weiteren Kommentaren
Informationen speichern (Cookie)

 Smileys einfügen